journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions

journal
https://www.readbyqxmd.com/read/30203330/idarucizumab-for-reversal-of-dabigatran-single-center-real-world-experience
#1
Marwan Sheikh-Taha
BACKGROUND: Idarucizumab is used to reverse the effects of dabigatran. Information on the use of idarucizumab in the clinical setting remains very limited. OBJECTIVE: The objective of this study was to describe clinical experience with idarucizumab in a large medical teaching center in the USA. METHODS: Patients who received idarucizumab to reverse the effects of dabigatran between 1 January 2016 and 30 June 2018 were studied. In patients with major bleeding, the efficacy of idarucizumab was assessed using criteria of the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee...
September 11, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30182350/efficacy-and-safety-of-the-use-of-non-vitamin-k-antagonist-oral-anticoagulants-in-patients-with-ischemic-heart-disease-a-meta-analysis-of-phase-iii-randomized-trials
#2
REVIEW
Linghua Fu, Wengen Zhu, Lin Huang, Jinzhu Hu, Jianyong Ma, Gregory Y H Lip, Kui Hong
BACKGROUND: There are conflicting published data on non-vitamin K antagonist oral anticoagulants (NOACs), with varying evidence of benefit or harm in acute coronary syndrome (ACS) and non-ACS cohorts. To explore the efficacy and safety of NOAC use in patients with ischemic heart disease (IHD), we conducted a meta-analysis of phase III randomized controlled trials (RCTs). METHODS: We systematically searched the Cochrane Library, PubMed, and Embase databases. A random-effect model was selected to pool the effect measurement estimates (hazard ratios [HRs] and 95% confidence intervals [CIs])...
September 4, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30155718/the-effect-of-bromodomain-and-extra-terminal-inhibitor-apabetalone-on-attenuated-coronary-atherosclerotic-plaque-insights-from-the-assure-trial
#3
Daisuke Shishikura, Yu Kataoka, Satoshi Honda, Kohei Takata, Susan W Kim, Jordan Andrews, Peter J Psaltis, Michael Sweeney, Ewelina Kulikowski, Jan Johansson, Norman C W Wong, Stephen J Nicholls
BACKGROUND: Apabetalone is a selective bromodomain and extra-terminal (BET) inhibitor which modulates lipid and inflammatory pathways implicated in atherosclerosis. The impact of apabetalone on attenuated coronary atherosclerotic plaque (AP), a measure of vulnerability, is unknown. METHODS: The ApoA-1 Synthesis Stimulation and intravascular Ultrasound for coronary atheroma Regression Evaluation (ASSURE; NCT01067820) study employed serial intravascular ultrasound (IVUS) measures of coronary atheroma in 281 patients treated with apabetalone or placebo for 26 weeks...
August 28, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30144017/biomarkers-of-thrombosis-in-st-segment-elevation-myocardial-infarction-a-substudy-of-the-atoll-trial-comparing-enoxaparin-versus-unfractionated-heparin
#4
Johanne Silvain, Stephen A O'Connor, Yan Yan, Mathieu Kerneis, Marie Hauguel-Moreau, Michel Zeitouni, Pavel Overtchouk, Annick Ankri, Delphine Brugier, Eric Vicaut, Patrick Ecollan, Sophie Galier, Jean-Philippe Collet, Gilles Montalescot
BACKGROUND: The aim was to compare the peri-procedural biomarkers of coagulation and platelet activation in patients randomly allocated to intravenous enoxaparin or unfractionated heparin (UFH) in the ATOLL randomized trial (NCT00718471). METHODS AND RESULTS: A total of 129 patients (n = 58 enoxaparin and n = 71 UFH) admitted for ST-segment elevation myocardial infarction (STEMI) treated by percutaneous coronary intervention (PCI) were included in this substudy of the ATOLL trial...
August 25, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30144016/fda-approval-of-angiotensin-ii-for-the-treatment-of-hypotension-in-adults-with-distributive-shock
#5
Fortunato Senatore, Gowraganahalli Jagadeesh, Martin Rose, Venkateswaran C Pillai, Sudharshan Hariharan, Ququan Liu, McDowell Tzu-Yun, Mohan K Sapru, Mary Ross Southworth, Norman Stockbridge
Distributive shock is a subset of shock marked by decreased systemic vascular resistance, organ hypoperfusion and altered oxygen extraction. Despite the use of intravenous fluids and either higher dose of catecholamines or other additional exogenous vasopressors to maintain blood pressure in the target range, the rate of mortality remains higher in patients with septic shock. Therefore, there is clearly an unmet need for additional safe and effective treatments. The use of angiotensin II to raise the mean arterial pressure (MAP) could provide additional therapy and the opportunity to evaluate a catecholamine-sparing effect by decreasing the dose of concomitant catecholamines while maintaining a target MAP...
August 25, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30144015/healthcare-utilization-and-expenditures-in-working-age-adults-with-atrial-fibrillation-the-effect-of-switching-from-warfarin-to-non-vitamin-k-oral-anticoagulants
#6
Xue Feng, Usha Sambamoorthi, Kim Innes, Traci LeMasters, Gregory Castelli, Nilanjana Dwibedi, Xi Tan
OBJECTIVE: Our objective was to evaluate the association between switching from warfarin to non-vitamin K oral anticoagulants (NOACs) and potential drug-drug interactions (DDIs), healthcare utilization, and expenditures in working-age adults with atrial fibrillation (AF). METHODS: We conducted a retrospective cohort study using data from 2010 to 2015 for patients who switched from warfarin to NOACs (switchers) and those who continued to receive warfarin (non-switchers)...
August 25, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30132141/early-and-late-stent-thrombosis-in-patients-with-versus-without-diabetes-mellitus-following-percutaneous-coronary-intervention-with-drug-eluting-stents-a-systematic-review-and-meta-analysis
#7
Jun Yuan, Guang Ma Xu
BACKGROUND: Nowadays, drug-eluting stents (DES) are most commonly used compared with bare metal stents (BMS) since the former are associated with significantly lower rates of revascularization following percutaneous coronary intervention (PCI). However, unpredictable in-stent thrombosis is a major concern with DES, especially in patients with diabetes mellitus. OBJECTIVE: In this analysis, we aimed to systematically compare early and late stent thrombosis in patients with versus without diabetes mellitus following PCI with DES...
August 22, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30132140/patients-priorities-for-oral-anticoagulation-therapy-in-non-valvular-atrial-fibrillation-a-multi-criteria-decision-analysis
#8
Marieke G M Weernink, Melissa C W Vaanholt, Catharina G M Groothuis-Oudshoorn, Clemens von Birgelen, Maarten J IJzerman, Janine A van Til
INTRODUCTION: Effectiveness of oral anticoagulants (OACs) is critically dependent on patients' adherence to intake regimens. We studied the relative impact of attributes related to effectiveness, safety, convenience, and costs on the value of OAC therapy from the perspective of patients with non-valvular atrial fibrillation. METHODS: Four attributes were identified by literature review and expert interviews: effectiveness (risk of ischemic stroke), safety (risk of major bleeding, minor bleeding, gastrointestinal complaints), convenience (intake frequency, diet restrictions, international normalized ratio [INR] blood monitoring, pill type/intake instructions), and out-of-pocket costs...
August 22, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/30066080/clinical-use-of-digitalis-a-state-of-the-art-review
#9
REVIEW
Thomas F Whayne
The history of digitalis is rich and interesting, with the first use usually attributed to William Withering and his study on the foxglove published in 1785. However, some knowledge of plants with digitalis-like effects used for congestive heart failure (CHF) was in evidence as early as Roman times. The active components of the foxglove (Digitalis purpurea and Digitalis lanata) are classified as cardiac glycosides or cardiotonic steroids and include the well-known digitalis leaf, digitoxin, and digoxin; ouabain is a rapid-acting glycoside usually obtained from Strophanthus gratus...
July 31, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29987548/oral-antiplatelet-therapy-for-secondary-prevention-of-acute-coronary-syndrome
#10
REVIEW
Jeffrey S Berger
Patients surviving an acute coronary syndrome (ACS) remain at increased risk of ischemic events long term. This paper reviews current evidence and guidelines for oral antiplatelet therapy for secondary prevention following ACS, with respect to decreased risk of ischemic events versus bleeding risk according to individual patient characteristics and risk factors. Specifically, data are reviewed from clinical studies of clopidogrel, prasugrel, ticagrelor and vorapaxar, as well as the results of systematic reviews and meta-analyses looking at the benefits and risks of oral antiplatelet therapy, and the relative merits of shorter versus longer duration of dual antiplatelet therapy, in different patient groups...
July 10, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29931556/acute-coronary-syndrome-in-cancer-patients
#11
REVIEW
Begum Yetis Sayin, Mehmet Ali Oto
Cardiologists are seeing an increasing number of oncology patients every day, and acute coronary syndrome (ACS) is one of the problems patients encounter during follow-up. Cardio-oncology is the care of patients with cancer and cardiovascular disease, whether overt or occult, already established or acquired during treatment. Cardiovascular complications can occur acutely during or shortly after treatment and persist as long-term effects for months to years after treatment. As a delayed effect of cancer treatment, cardiovascular damage can occur months to years after the initial treatment...
June 22, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29926351/cost-effectiveness-analysis-of-sacubitril-valsartan-compared-with-enalapril-in-patients-with-heart-failure-with-reduced-ejection-fraction-in-thailand
#12
Rungroj Krittayaphong, Unchalee Permsuwan
BACKGROUND: Sacubitril-valsartan is a new medication that has recently been recommended as a replacement for enalapril in the treatment of patients with heart failure with reduced ejection fraction (HFrEF). OBJECTIVE: This study aimed to determine the cost effectiveness of sacubitril-valsartan compared with enalapril. METHODS: An analytical decision model was developed to estimate the long-term costs and outcomes from a healthcare perspective...
June 21, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29971596/association-between-high-dose-spironolactone-and-decongestion-in-patients-with-acute-heart-failure-an-observational-retrospective-study
#13
Chris J Kapelios, Maria Bonou, Paraskevi Vogiatzi, George Tzanis, Polyxeni Mantzouratou, Lars H Lund, John Barbetseas
BACKGROUND: Acute congestive heart failure (ACHF) is a state of severe, secondary hyperaldosteronism. Relief of congestion has prognostic implications. Our aim was to assess associations between high-dose spironolactone and (1) decongestion and (2) safety in patients with ACHF. METHODS: The charts of 20 patients who were hospitalized with ACHF and received high doses of spironolactone (75-300 mg daily, group A) on top of standard of care (SOC) treatment were retrospectively studied and compared with the ones of 20 matched patients who received SOC treatment alone (group B)...
October 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29948822/efficacy-and-safety-of-intravenous-tenecteplase-bolus-in-acute-ischemic-stroke-results-of-two-open-label-multicenter-trials
#14
Tirppur C R Ramakrishnan, Somasundaram Kumaravelu, Sunil K Narayan, Sai S Buddha, Ch Murali, Palakkapparampil H A Majeed, Salvadeeswaran Meenakshi-Sundaram, Rustom S Wadia, Vikram Sharma, Indraneel Basu, Pamidimukkala Vijaya, Kizhakkaniyakath A Salam, Shahid Barmare, Zubin Vaid, K K Nirmal Raj, Pandurang R Wattamwar, Konbappan Asokan, Vijaykumar Dhonge, Shankara Nellikunja, Deepak Namjoshi, Rangasetty Srinivasa, Deepak S Laddhad, Shirish D Deshpande, Balakrishnan Raghunath, Jayantee Kalita, Mritunjai Kumar, Usha K Misra, Methil Pradeep
BACKGROUND: Tenecteplase (TNK-tPA) is a promising third-generation plasminogen activator, because of its greater fibrin specificity and longer half-life than alteplase. There is a paucity of studies on intravenous thrombolysis using TNK-tPA in developing countries. The present study has been undertaken to compare the efficacy and safety of TNK-tPA with alteplase. METHODS: Two studies were conducted. Study I was an open-label, randomized study in which two doses of TNK-tPA (0...
October 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29845546/treatment-with-mannitol-is-associated-with-increased-risk-for-in-hospital-mortality-in-patients-with-acute-ischemic-stroke-and-cerebral-edema
#15
Marianthi Papagianni, Konstantinos Tziomalos, Stavroula Kostaki, Stella-Maria Angelopoulou, Konstantinos Christou, Stella D Bouziana, Maria Vergou, Triantafyllos Didangelos, Christos Savopoulos, Apostolos I Hatzitolios
BACKGROUND: Current guidelines state that osmotic therapy is reasonable in patients with clinical deterioration from cerebral infarction-related cerebral edema. However, there are limited data on the safety and efficacy of this therapy. We aimed to evaluate the effect of mannitol on the outcome of ischemic stroke-related cerebral edema. METHODS AND RESULTS: We prospectively studied 922 consecutive patients admitted with acute ischemic stroke. Patients who showed space-occupying brain edema with tissue shifts compressing the midline structures received mannitol...
October 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29633091/vitamins-for-prevention-of-contrast-induced-acute-kidney-injury-a-systematic-review-and-trial-sequential-analysis
#16
REVIEW
Yongxing Xu, Xinming Zheng, Boran Liang, Jianjun Gao, Zhaoyan Gu
BACKGROUND: To date, universally accepted preventive measures for contrast-induced acute kidney injury (CI-AKI) do not exist, and they warrant further research. OBJECTIVE: The purpose of this study was to evaluate the efficacy of vitamins, including vitamin C and E, for prevention of CI-AKI. METHODS: We electronically searched the MEDLINE, EMBASE, and Cochrane databases. The outcome of interest was the incidence of CI-AKI. RESULTS: A total of 19 studies were included in this meta-analysis...
October 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29623658/atrial-fibrillation-in-patients-with-heart-failure-current-state-and-future-directions
#17
REVIEW
Tuoyo O Mene-Afejuku, Persio D López, Adedoyin Akinlonu, Carissa Dumancas, Ferdinand Visco, Savi Mushiyev, Gerald Pekler
Heart failure affects nearly 26 million people worldwide. Patients with heart failure are frequently affected with atrial fibrillation, and the interrelation between these pathologies is complex. Atrial fibrillation shares the same risk factors as heart failure. Moreover, it is associated with a higher-risk baseline clinical status and higher mortality rates in patients with heart failure. The mechanisms by which atrial fibrillation occurs in a failing heart are incompletely understood, but animal studies suggest they differ from those that occur in a healthy heart...
October 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29748918/self-reported-non-adherence-to-medication-in-japanese-patients-with-cardiovascular-diseases
#18
Tsuyoshi Suzuki, Tsuyoshi Shiga, Hisako Omori, Fujio Tatsumi, Katsuji Nishimura, Nobuhisa Hagiwara
OBJECTIVE: Non-adherence to medication is an important problem in cardiovascular treatment. The aim of this study was to assess self-reported non-adherence in Japanese patients with cardiovascular disease. METHODS: A total of 1372 outpatients at three university hospitals who completed self-reported questionnaires were analyzed in this prospective study (mean age 67 ± 12 years; 31% female). Self-reported adherence to cardiovascular drugs was measured with a modified Siegal scale...
August 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29691803/association-of-beta-blockers-with-survival-on-patients-presenting-with-acs-treated-with-pci-a-propensity-score-analysis-from-the-bleemacs-registry
#19
Fabrizio D'Ascenzo, Dario Celentani, Alessandro Brustio, Alberto Grosso, Sergio Raposeiras-Roubín, Emad Abu-Assi, Jose Paulo Simao Henriques, Jorge Saucedo, José Ramón González-Juanatey, Stephen B Wilton, Wouter J Kikkert, Iván Nuñez-Gil, Albert Ariza-Sole, Xiantao Song, Dimitrios Alexopoulos, Christoph Liebetrau, Tetsuma Kawaji, Zenon Huczek, Shao-Ping Nie, Toshiharu Fujii, Luis Correia, Masa-Aki Kawashiri, José María García-Acuña, Danielle Southern, Emilio Alfonso, Belén Terol, Alberto Garay, Dongfeng Zhang, Yalei Chen, Ioanna Xanthopoulou, Neriman Osman, Helge Möllmann, Hiroki Shiomi, Michal Kowara, Krzysztof Filipiak, Xiao Wang, Yan Yan, Jing-Yao Fan, Yuji Ikari, Takuya Nakahayshi, Kenji Sakata, Masakazu Yamagishi, Oliver Kalpak, Sasko Kedev, Claudio Moretti, Maurizio D'Amico, Fiorenzo Gaita
PURPOSE: The aim was to evaluate prognostic value of beta-blocker (BB) administration in acute coronary syndromes (ACS) patients in the percutaneous coronary intervention (PCI) era. METHODS AND RESULTS: The BleeMACS project is a multicenter, observational, retrospective registry enrolling patients with ACS worldwide in 15 hospitals. Patients discharged with BB therapy were compared to those discharged without a BB before and after propensity score with matching...
August 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29623672/a-systematic-review-on-the-protective-effect-of-n-acetyl-cysteine-against-diabetes-associated-cardiovascular-complications
#20
REVIEW
Phiwayinkosi V Dludla, Stephanie C Dias, Nnini Obonye, Rabia Johnson, Johan Louw, Bongani B Nkambule
INTRODUCTION: Heart failure is the leading cause of death in patients with diabetes. No treatment currently exists to specifically protect these patients at risk of developing cardiovascular complications. Accelerated oxidative stress-induced tissue damage due to persistent hyperglycemia is one of the major factors implicated in deteriorated cardiac function within a diabetic state. N-acetyl cysteine (NAC), through its enhanced capacity to endogenously synthesize glutathione, a potent antioxidant, has displayed abundant health-promoting properties and has a favorable safety profile...
August 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
journal
journal
35888
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"